TADALAFIL PROVES EFFECTIVE THERAPY FOR PULMONARY HYPERTENSION
(Tuesday, October 28, 10:30 AM EST)
New research shows that the erectile dysfunction drug, tadalafil, may be an effective adjunct therapy for patients with pulmonary arterial hypertension (PAH). Italian researchers randomized 405 patients with PAH, of whom 53 percent were taking concomitant bosentan, to two study arms. The groups received either tadalafil or placebo orally once daily as monotherapy or as add-on therapy to bosentan. Compared with placebo, tadalafil, 40 mg, increased 6-minute walk distance, delayed the time to clinical worsening, and improved six of the eight short form (SF)-36 domains. In addition, tadalafil, 40 mg, increased cardiac output and reduced pulmonary artery pressures and pulmonary vascular resistance compared with baseline. Discontinuation due to adverse events was low (11 percent for tadalafil vs. 16 percent for placebo). Researchers conclude that tadalafil may provide an effective oral, once-daily therapy that can be combined with bosentan therapy for patients with PAH.
OMEGA-3 FATTY ACID LEVELS MAY AFFECT SLEEP APNEA SEVERITY
(Tuesday, October 28, 1:00 PM EST)
The level of omega-3 fatty acids found in a patient's blood may determine the severity of his or her sleep apnea. Researchers from the University of Missouri, Kansas City, MO, tested fatty acid levels in 350 subjects with apnea-hypopnea index scores of 0 to 104. Results showed that lower levels of docosahexaenoic acid (DHA), a type of omega-3 fatty acid, was associated with increased apnea severity, even after controlling for age, sex, race, smoking, BMI, fish intake, omega-3 supplementation, flaxseed oil supplementatio
|Contact: Jennifer Stawarz|
American College of Chest Physicians